Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
01:58am, Wednesday, 24'th Apr 2024
Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.
Roche Q1 sales down 6% on forex effect, loss of COVID revenue
01:14am, Wednesday, 24'th Apr 2024
Roche said on Wednesday its first-quarter sales slipped 6% as the loss on COVID-19 related revenue was partly offset by further gains in eye drug Vabysmo.
Roche CEO Thomas Schinecker: “We had a strong start into the year, with both our divisions reporting high single digit growth in their base business – excluding COVID-19 sales. After this quarter,
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
11:16am, Friday, 19'th Apr 2024
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
01:00am, Friday, 19'th Apr 2024
Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour r
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
04:35pm, Thursday, 18'th Apr 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecens
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the Phase III OCARINA II study (S31.006) of Ocrevus® (ocre
Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS® (ocrelizumab), an investigational twice-yearly, 10-minute subc
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
08:36am, Monday, 15'th Apr 2024
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
David Roche: Israeli escalation against Iran is 'baked in the cake'
02:04am, Monday, 15'th Apr 2024
David Roche, president and global strategist at Independent Strategy, discusses Iran's drone and missile attack on Israel and says "you have all degrees of escalation that are possible, but escalation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survi
Why Roche Holdings Stock Popped Today
06:33pm, Thursday, 11'th Apr 2024
A Roche-Lilly collaboration to test for indications of Alzheimer's disease won FDA Breakthrough Device Designation on Thursday. The new test will now proceed to clinical trials needed for full FDA app
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
11:42am, Tuesday, 09'th Apr 2024
The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.
Lido Advisors' Gina Sanchez offers 3 buys and a bail: Roche, TotalEnergies, AB InBev & Arm
02:31pm, Thursday, 28'th Mar 2024
Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three buys and a bail, including Roche, TotalEnergies, AB InBev, and Arm.
The bottom of interest rate in the new cycle will be much higher: David Roche and Euan Munro
12:30am, Monday, 25'th Mar 2024
Euan Munro of Newton Investment and David Roche of Independent Strategy discuss the possibility of the Federal Reserve reducing interest rates against the backdrop of high government spending and budg
